Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cellular Signalling

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cellsig.2014.03.032PMID 24705026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans

  2014cited by this paper
• Distinct Pathways Regulated by RET and Estrogen Receptor in Luminal Breast Cancer Demonstrate the Biological Basis for Combination Therapy

  2014cited by this paper
• Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

  2013cited by this paper
• RET inhibition: implications in cancer therapy

  2013cited by this paper
• Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer.

  2013cited by this paper
• Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

  2013cited by this paper
• The new kid on the block: RET in lung cancer.

  2013cited by this paper
• RET fusion gene: Translation to personalized lung cancer therapy

  2013cited by this paper
• A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

  2013cited by this paper
• Signaling pathways in follicular cell-derived thyroid carcinomas (review).

  2013cited by this paper
• Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

  2013cited by this paper
• GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

  2013cited by this paper
• Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer

  2013cited by this paper
• Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells

  2013cited by this paper
• Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

  2013cited by this paper
• Cabozantinib in progressive medullary thyroid cancer.

  2013cited by this paper
• Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

  2013cited by this paper
• Ponatinib in refractory Philadelphia chromosome-positive leukemias.

  2012cited by this paper
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

  2012cited by this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012cited by this paper
• Critical Role of GFRα1 in the Development and Function of the Main Olfactory System

  2012cited by this paper
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  2011cited by this paper
• Rap1GAP interacts with RET and suppresses GDNF-induced neurite outgrowth

  2011cited by this paper
• Development of RET kinase inhibitors for targeted cancer therapy.

  2011cited by this paper
• Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

  2011cited by this paper
• Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism*

  2011cited by this paper
• RET in breast cancer: functional and therapeutic implications.

  2011cited by this paper
• Protein-tyrosine Phosphatase SHP2 Contributes to GDNF Neurotrophic Activity through Direct Binding to Phospho-Tyr687 in the RET Receptor Tyrosine Kinase*

  2010cited by this paper
• Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

  2010cited by this paper
• Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

  2010cited by this paper
• Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

  2010cited by this paper
• Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation

  2010cited by this paper
• Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

  2010cited by this paper
• Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.

  2010cited by this paper
• Role of NF-kappaB in thyroid cancer.

  2010cited by this paper
• XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway

  2009cited by this paper
• The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

  2009cited by this paper
• Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

  2009cited by this paper
• Biological determinants of endocrine resistance in breast cancer

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.

  2008cited by this paper
• Development of satellite glia in mouse sympathetic ganglia: GDNF and GFRα1 are not essential

  2008cited by this paper
• Diminished Ret expression compromises neuronal survival in the colon and causes intestinal aganglionosis in mice.

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008cited by this paper
• A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.

  2008cited by this paper
• Motesanib diphosphate in progressive differentiated thyroid cancer.

  2008cited by this paper
• Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

  2007cited by this paper
• A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.

  2007cited by this paper
• Conditional ablation of GFRα1 in postmigratory enteric neurons triggers unconventional neuronal death in the colon and causes a Hirschsprung's disease phenotype

  2007cited by this paper
• Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting*

  2007cited by this paper
• A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.

  2007cited by this paper
• RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface

  2007cited by this paper
• RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.

  2006cited by this paper
• Current concepts in RET-related genetics, signaling and therapeutics.

  2006cited by this paper
• Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain*

  2006cited by this paper
• Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor alpha4 impairs thyroid calcitonin production in young mice.

  2006cited by this paper
• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  2006cited by this paper
• Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.

  2006cited by this paper
• Cooperation between GDNF/Ret and ephrinA/EphA4 signals for motor-axon pathway selection in the limb.

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• Critical and distinct roles for key RET tyrosine docking sites in renal development.

  2006cited by this paper
• Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells

  2006cited by this paper
• BAY 43-9006 inhibition of oncogenic RET mutants.

  2006cited by this paper
• Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow

  2005cited by this paper
• The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

  2005cited by this paper
• RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.

  2005cited by this paper
• GDNF and GFR 1 Promote Differentiation and Tangential Migration of Cortical GABAergic Neurons

  2005cited by this paper
• The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells

  2004cited by this paper
• A Targeting Mutation of Tyrosine 1062 in Ret Causes a Marked Decrease of Enteric Neurons and Renal Hypoplasia

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Central Role of the Threonine Residue within the p+1 Loop of Receptor Tyrosine Kinase in STAT3 Constitutive Phosphorylation in Metastatic Cancer Cells

  2004cited by this paper
• Tyrosine 981, a Novel Ret Autophosphorylation Site, Binds c-Src to Mediate Neuronal Survival*

  2004cited by this paper
• Chronic expression of RET/PTC 3 enhances basal and insulin‐stimulated PI3 kinase/AKT signaling and increases IRS‐2 expression in FRTL‐5 thyroid cells

  2004cited by this paper
• Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.

  2004cited by this paper
• Identification of RET Autophosphorylation Sites by Mass Spectrometry*

  2004cited by this paper
• Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the Cdc42-associated Tyrosine Kinase ACK1*

  2004cited by this paper
• Neurturin signalling via GFRα2 is essential for innervation of glandular but not muscle targets of sacral parasympathetic ganglion neurons

  2004cited by this paper
• Dok-6, a Novel p62 Dok Family Member, Promotes Ret-mediated Neurite Outgrowth*

  2004cited by this paper
• Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

  2004cited by this paper
• Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca.

  2003cited by this paper
• Alimentary tract innervation deficits and dysfunction in mice lacking GDNF family receptor alpha2.

  2003cited by this paper
• Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient.

  2003cited by this paper
• ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

  2002cited by this paper
• Novel Mechanism of Regulation of Rac Activity and Lamellipodia Formation by RET Tyrosine Kinase*

  2002cited by this paper
• RET/PTC rearrangement in thyroid tumors

  2002cited by this paper
• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

  2002cited by this paper
• Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine Kinase

  2002cited by this paper
• Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.

  2002cited by this paper
• Role of Dok1 in Cell Signaling Mediated by RET Tyrosine Kinase*

  2002cited by this paper
• Effects of cerebral ischemia in mice deficient in Persephin

  2002cited by this paper
• Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade

  2001cited by this paper
• The Sensitivity of Activated Cys Ret Mutants to Glial Cell Line-Derived Neurotrophic Factor Is Mandatory To Rescue Neuroectodermic Cells from Apoptosis

  2001cited by this paper
• Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.

  2001cited by this paper
• Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation

  2001cited by this paper
• Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction

  2001cited by this paper
• MEN2A-RET-induced cellular transformation by activation of STAT3

  2001cited by this paper

• Familial Thyroid Cancers Syndromes.

  2025cites this paper
• Thyroid C-Cell Biology and Oncogenic Transformation.

  2025cites this paper
• RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update

  2025cites this paper
• Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.

  2025cites this paper
• Specific genomic alterations and aggressive clinical features of sporadic thyroid carcinomas in children and adolescents: findings from an in-house cohort study

  2025cites this paper
• Stable G quadruplex formed in promoter region of oncogene RET in physiological solution conditions

  2024cites this paper
• REThinking the role of the RET oncogene in breast cancer

  2024influential citation
• Phase separation of SPIN1 through its IDR facilitates histone methylation readout and tumorigenesis

  2024cites this paper
• Modeling RET-Rearranged Non-Small Cell Lung Cancer (NSCLC): Generation of Lung Progenitor Cells (LPCs) from Patient-Derived Induced Pluripotent Stem Cells (iPSCs)

  2023cites this paper
• Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

  2023cites this paper
• RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity

  2023cites this paper
• Recent Developments in Mitochondrial G-Quadruplex Recognising Fluorescent Probes: A Review

  2023cites this paper
• A network map of GDNF/RET signaling pathway in physiological and pathological conditions

  2023cites this paper
• RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.

  2023cites this paper
• Genomic and epigenomic profile of thyroid cancer.

  2022cites this paper
• Glaucoma-TrEl: A web-based interactive database to build evidence-based hypotheses on the role of trace elements in glaucoma

  2022cites this paper
• RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.

  2022cites this paper
• The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET

  2022cites this paper
• Atropisomerism in the Pharmaceutically Relevant Realm

  2022cites this paper
• LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer

  2022cites this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.

  2022cites this paper
• Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes

  2022cites this paper
• Ultrasonic Characteristics of Medullary Thyroid Carcinoma

  2021cites this paper
• Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics

  2021cites this paper
• Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment.

  2021cites this paper
• Multiple endocrine neoplasia 2A with RET mutation p.Cys611Tyr

  2021cites this paper
• Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity

  2021cites this paper
• RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

  2020cites this paper
• Roles of the RET Proto-oncogene in Cancer and Development

  2020cites this paper
• Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.

  2020cites this paper
• Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration

  2020cites this paper
• Systems-level differential gene expression analysis reveals new genetic variants of oral cancer

  2020cites this paper
• Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

  2020cites this paper
• Intracellular RET signaling pathways activated by GDNF

  2020cites this paper
• Plasma membrane localization of the GFL receptor components: a nexus for receptor crosstalk

  2020cites this paper
• Ret Receptor Has Distinct Alterations and Functions in Breast Cancer

  2020cites this paper
• Molecular target therapy and immunotherapy of rare lung tumours

  2019cites this paper
• Silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis via suppression of the RTK signaling pathway

  2019cites this paper
• Receptor‐guided 3D‐QSAR Study of Anilinoquinazolines as RET Receptor Tyrosine Kinase Antagonists

  2019cites this paper
• Targeting RET-rearranged non-small-cell lung cancer: future prospects

  2019cites this paper
• OTT_A_171665 7857..7864

  2019cites this paper
• Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

  2019cites this paper
• Multiple Endocrine Neoplasia Type 2A Patient with Metastatic Medullary Thyroid Carcinoma and Unilateral Multicentric Pheochromocytoma: A Case Report and Literature Review

  2018cites this paper
• Medullary Thyroid Carcinoma (MTC): Diagnosis, Treatment and Follow-Up

  2018cites this paper
• Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity

  2018cites this paper
• Identification of fused pyrimidines as interleukin 17 secretion inhibitors.

  2018cites this paper
• Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.

  2018cites this paper
• Role of artemin in non‐small cell lung cancer

  2018cites this paper
• Roles of Selenoprotein M (SELENOM) in Hypothalamic Leptin Signaling and Calcium Regulation.

  2018cites this paper
• Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer

  2018cites this paper
• Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer

  2018cites this paper
• Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

  2018cites this paper
• Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression.

  2017cites this paper
• RET kinase inhibitors: a review of recent patents (2012–2015)

  2017cites this paper
• The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A

  2017cites this paper
• Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.

  2017cites this paper
• Structure and function of RET in multiple endocrine neoplasia type 2.

  2017cites this paper
• Molecular pathology of lung cancer: current status and perspectives

  2017cites this paper
• RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).

  2017cites this paper
• The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

  2017cites this paper
• EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression

  2017cites this paper
• Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead

  2017cites this paper
• Minor-Driver Mutant

  2017cites this paper
• Molecular genetics of syndromic and non‐syndromic forms of parathyroid carcinoma

  2017cites this paper
• Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

  2016cites this paper
• Emerging targeted therapies in non-small cell lung cancer

  2016influential citation
• An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells

  2016cites this paper
• Signaling pathways in medullary thyroid carcinoma: therapeutic implications

  2016cites this paper
• Molecular Mechanisms of Disease: The RET Proto-oncogene

  2016cites this paper
• Dynamics of mRNA and microRNA expression in the estrogen response of breast cancer cells

  2016cites this paper
• QUINAZOLINE + BASED ! ALPHA 1 + ADRENOCEPTOR ! ANTAGONISTS ! AND ! PROSTATE ! CANCER !

  2016cites this paper
• Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review)

  2016cites this paper
• RET protein is overexpressed in oral squamous cell carcinoma

  2016cites this paper
• Systemic treatment and management approaches for medullary thyroid cancer.

  2016cites this paper
• in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.

  2016cites this paper
• Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.

  2016cites this paper
• Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

  2016cites this paper
• Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy

  2016cites this paper
• RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements

  2016influential citation
• The Management of Medullary Thyroid Carcinoma in the Era of Targeted Therapy

  2016cites this paper
• Unregulated long non-coding RNA-AK058003 promotes the proliferation, invasion and metastasis of breast cancer by regulating the expression levels of the γ-synuclein gene.

  2015cites this paper
• The RET Receptor Family

  2015cites this paper
• A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos

  2015cites this paper
• Alteration of WWOX in human cancer, a clinical view

  2015cites this paper
• Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies.

  2015cites this paper
• The histone code reader SPIN1 controls RET signaling in liposarcoma

  2015cites this paper
• Medullary Thyroid Carcinoma: from diagnosis to treatment

  2015cites this paper
• Thyroid C-Cell Biology and Oncogenic Transformation.

  2015cites this paper
• The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells

  2015cites this paper
• Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.

  2015cites this paper
• Etude de la voie de signalisation Artn/Gfrɑ3 dans le pancréas

  2014influential citation